Kellen Pharmaceutical: Multiple drugs are expected to win bids in the twelfth round of national centralized drug procurement.

Kelong Pharmaceutical announced that on July 31, 2026, the company and its subsidiaries will participate in the twelfth batch of national centralized drug procurement bidding, with 14 products including sacubitril/valsartan tablets expected to win bids. From 2024 to 2025, some of the products expected to win bids have reported sales performance, such as sacubitril/valsartan tablets in the 50mg specification, which are projected to generate sales revenues of 4.637 million yuan and 6.3185 million yuan in 2024 and 2025, respectively. If procurement contracts are signed and implemented subsequently, it will expand product sales, increase market share, and enhance brand influence, but there are uncertainties regarding the signing of procurement agreements and their impact on performance.